AstraZeneca plc (AZN) Ordinary US$0.25

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
AstraZeneca's Calquence receives European Commission approval
6 June 2025 08:05
(Sharecast News) - Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens of its chronic lymphocytic leukaemia candidate Calquence in a...
-
EU recommends AstraZeneca bladder cancer treatment for approval
27 May 2025 08:36
(Sharecast News) - EU regulators have recommended AstraZeneca's Imfinzi for approval in the treatment muscle-invasive bladder cancer (MIBC).
-
London close: Stocks finish choppy week in the black
16 May 2025 16:32
(Sharecast News) - London equities ended the week higher on Friday, supported by gains in pharmaceutical and energy stocks.
-
London close: Stocks rally on US-China tariff deal
12 May 2025 16:30
(Sharecast News) - London stocks ended higher on Monday as investors welcomed news of a temporary trade agreement between the United States and China that will see a rollback of some tariffs.
-
Pharma stocks slide as Trump threatens price cuts in US
12 May 2025 10:13
(Sharecast News) - Shares in pharmaceutical companies fell on Monday after US President Donald Trump threatened to sign an executive order to slash the price of prescription drugs for Americans.
-
Sunday newspaper round-up: US-China, Aerospace, Pharma
11 May 2025 14:38
(Sharecast News) - The US president said talks with China that were taking place in Geneva had achieved a "total reset" in the two countries' trade relations. Without elaborating, Donald Trump...
-
London close: FTSE snaps 16-day win streak ahead of Fed
7 May 2025 15:05
(Sharecast News) - London stocks ended lower on Wednesday, with the top-flight index snapping a 16-day winning streak as investor caution ahead of the US Federal Reserve's policy decision weighed on...
-
GSK, AstraZeneca slide after FDA unveils new vaccine lead
7 May 2025 11:32
(Sharecast News) - Shares in GSK and AstraZeneca came under pressure on Wednesday, after vaccine-sceptic Vinay Prasad was appointed to a key role at the US Food and Drug Administration.
-
AstraZeneca receives 'positive high-level results' results from Enhertu trial
7 May 2025 09:23
(Sharecast News) - Drugmaker AstraZeneca revealed on Wednesday that it had received "positive high-level results" from a Phase III trial on its specifically engineered HER2-directed DXd antibody...
-
AstraZeneca's Calquence gets Europe approval for MCL
6 May 2025 08:02
(Sharecast News) - AstraZeneca announced on Tuesday that it has secured European Commission approval for 'Calquence', or acalabrutinib, in combination with bendamustine and rituximab for the...
-
AstraZeneca's Breztri meets all primary endpoints in asthma trials
2 May 2025 10:00
(Sharecast News) - AstraZeneca announced on Friday that its inhaled triple-combination therapy 'Breztri Aerosphere' met all primary endpoints in two phase three trials, delivering statistically...
-
AstraZeneca receives positive Phase III trial results from Enhertu study
22 April 2025 08:05
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it had received "positive high-level results" from a Phase III trial on its Enhertu candidate, developed in conjunction with Daiichi...
Company announcements Announcements
-
Fixed-duration Calquence approved in EU for 1L CLL
6 June 2025 07:00
AstraZeneca
-
Block listing Interim Review
2 June 2025 15:05
AstraZeneca
-
Total Voting Rights
2 June 2025 15:00
AstraZeneca
-
Imfinzi recommended in EU for bladder cancer
27 May 2025 07:00
AstraZeneca
-
Director/PDMR Shareholding
23 May 2025 10:00
AstraZeneca
-
Director Declaration
21 May 2025 13:45
AstraZeneca
-
Imfinzi improved DFS in early bladder cancer
9 May 2025 07:00
AstraZeneca
-
Enhertu improved pCR in early-stage breast cancer
7 May 2025 07:30
AstraZeneca
-
Calquence combination approved in EU for 1L MCL
6 May 2025 07:00
AstraZeneca
-
Breztri met primary endpoints in Ph3 asthma trials
2 May 2025 07:00
AstraZeneca
-
Total Voting Rights
1 May 2025 15:00
AstraZeneca
-
Fixed-duration Calquence recommended in EU for CLL
29 April 2025 07:10
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.